Evaluation of Diclofenaceffect on oxidative stressed mice

Zoubair, Benkhassi

doi:10.18782/2320-7051.2232

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASA decreased glucose blood levels and increased serum arginine vasopressin hormone levels after 5 weeks of oral treatment (150 mg/kg/day) in STZ-induced diabetic mice [52]. Furthermore, in vivo data suggest that a dose of 30 mg/kg of ASA was able to prevent oxidative damages caused by an intraperitoneal injection of peroxide hydrogen in mice and established the redox homeostasis [53]. Moreover, recent studies also showed that oral administration of Zn(ASA) 2 complex to Zucker diabetic fatty rats reduced plasma glucose-levels and prevented diabetic cardiomyopathy [54].…”

Section: Acetylsalicylic Acidmentioning

confidence: 95%

The Use of Bioactive Compounds in Hyperglycemia- and Amyloid Fibrils-Induced Toxicity in Type 2 Diabetes and Alzheimer’s Disease

2022

View full text Add to dashboard Cite

It has become increasingly apparent that defective insulin signaling may increase the risk for developing Alzheimer’s disease (AD), influence neurodegeneration through promotion of amyloid formation or by increasing inflammatory responses to intraneuronal β-amyloid. Recent work has demonstrated that hyperglycemia is linked to cognitive decline, with elevated levels of glucose causing oxidative stress in vulnerable tissues such as the brain. The ability of β-amyloid peptide to form β-sheet-rich aggregates and induce apoptosis has made amyloid fibrils a leading target for the development of novel pharmacotherapies used in managing and treatment of neuropathological conditions such as AD-related cognitive decline. Additionally, deposits of β-sheets folded amylin, a glucose homeostasis regulator, are also present in diabetic patients. Thus, therapeutic compounds capable of reducing intracellular protein aggregation in models of neurodegenerative disorders may prove useful in ameliorating type 2 diabetes mellitus symptoms. Furthermore, both diabetes and neurodegenerative conditions, such as AD, are characterized by chronic inflammatory responses accompanied by the presence of dysregulated inflammatory biomarkers. This review presents current evidence describing the role of various small bioactive molecules known to ameliorate amyloidosis and subsequent effects in prevention and development of diabetes and AD. It also highlights the potential efficacy of peptide–drug conjugates capable of targeting intracellular targets.

show abstract

Section: Acetylsalicylic Acidmentioning

confidence: 95%